Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07269301 | A Study to Learn How the Body Processes the Study Medicine PF-07328948 in People With and Without Reduced Liver Function | PHASE1 | RECRUITING | 26 | — | — | Dec 22, 2025 | Feb 23, 2027 | May 26, 2026 | 3 | United States |
Fu is the fraction of unbound drug in plasma, which is calculated by Cu/C (where Cu represents unbound concentration and C represents total concentration).
AUCinf is the area under the plasma concentration-time profile from time zero extrapolated to infinite time. AUCinf,u is the unbound AUCinf.
Cmax is the maximum plasma concentration. Cmax,u is the unbound Cmax.
| Arm | Type | Description |
|---|---|---|
| Group 1: PF-07328948 participants with severe hepatic impairment | EXPERIMENTAL | Participants with severe hepatic impairment will receive a single dose of PF-07328948, administered orally as 1 PF-07328948 tablet. |
| Group 2: PF-07328948 participants with moderate hepatic impairment | EXPERIMENTAL | Participants with moderate hepatic impairment will receive a single dose of PF-07328948, administered orally as 1 PF-07328948 tablet. |
| Group 3: PF-07328948 participants with mild hepatic impairment | EXPERIMENTAL | Participants with mild hepatic impairment will receive a single dose of PF-07328948, administered orally as 1 PF-07328948 tablet. |
| Group 4: PF-07328948 participants without hepatic impairment | EXPERIMENTAL | Participants without hepatic impairment will receive a single dose of PF-07328948, administered orally as 1 PF-07328948 tablet. |
| Name | Type | Description |
|---|---|---|
| PF-07328948 | DRUG | PF-07328948, 1 tablet orally, once on Day 1 |
Inclusion Criteria: * Male or female of nonchildbearing potential, between the ages of 18 (inclusive) and 75 years, at the screening visit. * Willing and able to comply with all scheduled visits, treatment plan, laboratory tests, lifestyle considerations, and other study procedures. * BMI of 17.5 t...